Ipca Laboratories Limited (IPCALAB.BO)

INR 1573.8

(3.81%)

Market Cap (In INR)

399.27 Billion

Revenue (In INR)

76.22 Billion

Net Income (In INR)

5.47 Billion

Avg. Volume

18.31 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1042.0-1708.7
PE
-
EPS
-
Beta Value
0.229
ISIN
INE571A01038
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Pranay Premchand Godha
Employee Count
-
Website
https://www.ipca.com
Ipo Date
2000-01-03
Details
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.